Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.450
-0.145-2.59%
Volume:92.87M
Turnover:504.61M
Market Cap:101.82B
PE:35.99
High:5.500
Open:5.500
Low:5.380
Close:5.595
52wk High:9.017
52wk Low:4.190
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.98
T/O Rate:0.50%
Dividend:0.12
Dividend Rate:2.25%
EPS(LYR):0.151
ROE:14.07%
ROA:7.51%
PB:2.68
PE(LYR):35.99
PS:2.59

Loading ...

CMB International Reaffirms Buy Rating for SBP Group with HK$8.70 Price Target

Stock News
·
Jul 09

Movement Alert|Sino Biopharmaceutical Rises 4.15% in Regular Trading, AstraZeneca and GSK Dual Partnerships Continue to Boost Sentiment

Market Focus
·
Jul 09

PRESS Digest -wall Street Journal - July 8

Reuters
·
Jul 08

UK Stocks-factors to Watch on July 8

Reuters
·
Jul 08

Sino Biopharma Unit Licenses Respiratory Drug Candidate to AstraZeneca in Up to $2.1 Billion Deal

MT Newswires Live
·
Jul 08

SBP Group Expands GSK Partnership; Secures China Rights for Blockbuster Respiratory Drugs Trelegy Ellipta and Anoro Ellipta

Bulletin Express
·
Jul 08

Hong Kong Market Midday Report: Hang Seng Index Gains 2.38%, Domestic Chip Stocks Surge

Stock News
·
Jul 08

Sino Biopharma Deepens GSK Tie, Wins China Commercialization Rights for Trelegy and Anoro Inhalers

Reuters
·
Jul 08

Sino Biopharmaceutical - Sbp Group Deepens Exclusive Strategic Collaboration with GSK for Respiratory Therapies in China

THOMSON REUTERS
·
Jul 08

Sino Biopharmaceutical - Co Will be Responsible for Importation, Distribution, Others for These Products in Mainland China

THOMSON REUTERS
·
Jul 08

Sino Biopharmaceutical - Sbp Group Obtains China Commercialisation Rights for Gsk's Trelegy Ellipta and Anoro Ellipta

THOMSON REUTERS
·
Jul 08

SBP GROUP Shares Surge Over 4% in Early Trading Following Exclusive Licensing Deal with AstraZeneca for TQC3721

Stock News
·
Jul 08

Stock Track | SBP GROUP Soars 5.39% Intraday on $1.9 Billion AstraZeneca Licensing Deal

Stock Track
·
Jul 08

Movement Alert|Sino Biopharmaceutical Rises 3.73% in Regular Trading, AstraZeneca Licensing Deal Worth Up to $1.9 Billion

Market Focus
·
Jul 08

Sino Biopharmaceutical Enters Exclusive License Agreement with Astrazeneca for Tqc3721

Reuters
·
Jul 08

Sino Biopharma Says Tqc3721 Posts Phase Iib COPD Data, Advances to Phase III in China

Reuters
·
Jul 08

Sino Biopharmaceutical - Eligible for $200 Mln Upfront, Milestones up to $1.9 Bln, and Tiered Royalties

THOMSON REUTERS
·
Jul 08

Sino Biopharmaceutical - Astrazeneca Granted Exclusive Rights to Tqc3721 Outside China

THOMSON REUTERS
·
Jul 08

Movement Alert|Sino Biopharmaceutical Falls 3.17% in Regular Trading, Trading at 4.9 HKD

Market Focus
·
Jul 07

Sino Biopharmaceutical Stock Rallies 6.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 06